Shire has hired investment bank Citi as an adviser following a wave of deals in the healthcare sector.
Johnson & Johnson turned in a solid first quarter Tuesday, topping analysts' profit and revenue estimates and increasing its 2014 earnings forecast by 5 cents a share.
Profile of 27-year-old Ethan Lewis, who has been creating products to sell to his fellow diabetics.
The Cefaly device uses a mild electric current to prevent migraines.
P&G is bringing the dentist into your bathroom a smartphone-connected toothbrush, a device that gives personalized advice to help people improve their brushing.
Johnson & Johnson and its subsidiaries were accused of promoting powerful psychiatric drugs for unapproved uses in children, seniors and disabled patients.
The family of Henrietta lacks, whose immortal cells made billions in medical research, won an ethical victory when they were given some power over HeLa cell information.
Henry Schein is the world's largest health care products and services company for doctors, dentists, and vets, and the stock has been on a tear. Stanley Bergman, Henry Schein chairman and CEO, shares where he sees dental and health care headed.
Johnson & Johnson reported higher-than-expected earnings as strong sales of prescription drugs and medical devices more than offset anemic growth of its consumer products.
Obama administration to scrap age restrictions on the sale of morning-after pills, making the emergency contraception available to women and girls of any age without a prescription.
Bristol-Myers Squibb and Merck stocks climbed higher Monday as analysts said billions stood to be made from treatment breakthroughs.
Keith Smith, Co-founder, Managing Partner at the Surgery Center of Oklahoma says that all funds are channeled to patient care, helping his team deliver quality healthcare and low costs.
Johnson & Johnson's stock has gained 22 percent on the year and trades at a higher P/E ratio than its competitors. It is not a good buy now, but a great hold, TheStreet.com says.
The rise of "superbugs," and pressure from the government and insurers, is driving hospitals to try all sorts of new approaches to stop their spread.
The pharmaceutical and medical devices company reported quarterly earnings and revenue Tuesday that exceeded Wall Street's expectations as growth of newer medicines for cancer, hepatitis C and blood clots offset declining sales of its treatments for heartburn and attention deficit disorder.
Roger Parloff, Fortune senior editor, says businesses are sprouting in states like Colorado and Washington, where selling cannabis is now legal.
If you smoke, you might have to pay thousands extra for employee-based health insurance under Obamacare starting next year.
On a First on CNBC interview, Cochlear CEO Chris Roberts tells CashFlow about his company's products and plans for global expansion.
An internal analysis conducted by Johnson & Johnson in 2011 estimated that the all-metal device would fail within five years in nearly 40 percent of patients who received it, newly disclosed court records show.
Pfizer's unit Zoetis plans to sell 86.1 million shares at between $22 and $25 each in an initial public offering.